Pixis Oncology
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics targeting hard-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, and management team will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference, August 5-6, 2024.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on overcoming difficult-to-treat cancers. The company is efficiently building next-generation therapeutics with potential as monotherapy and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN in the tumor stroma, and PYX-106, a fully human Siglec-15-targeted antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical trials in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and address the underlying pathology generated by cancer that enables uncontrolled proliferation and immune evasion. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel strategies to target a broad range of solid tumors resistant to current standards of care. For more information, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or similar expressions or variations thereof, although not all forward-looking statements contain these words. We cannot assure you that the events or circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, the factors identified herein, the factors discussed in the “Risk Factors” section of Part II, Item 1A of the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2024, and other filings with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for the Company’s management to predict all risk factors, nor can it assess the impact that all factors may have on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in the forward-looking statements. In addition, “we believe” and similar statements reflect the Company’s beliefs and opinions with respect to the relevant subject matter. Such statements are based on information available to the Company as of the date hereof, and the Company believes such information provides a reasonable basis for such statements, but such information may be limited or incomplete, and the Company’s statements should not be construed as an indication that the Company has conducted a thorough investigation or review of all relevant information available to it. These statements are inherently uncertain, and investors are cautioned not to place undue reliance on them. Except as required by law, the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date of such statements.
The story continues
Contact Pyxis Oncology
Pamela Connelly
CFO and COO
email address
